J.Safra Asset Management Corp Acquires Shares of 10,412 Astrazeneca Plc $AZN

J.Safra Asset Management Corp bought a new position in Astrazeneca Plc (NYSE:AZN) during the 4th quarter, Holdings Channel.com reports. The firm bought 10,412 shares of the company’s stock, valued at approximately $1,827,000.

Several other hedge funds also recently made changes to their positions in AZN. Triumph Capital Management purchased a new stake in Astrazeneca during the 3rd quarter valued at $25,000. Bangor Savings Bank increased its position in shares of Astrazeneca by 102.7% in the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock valued at $28,000 after acquiring an additional 154 shares during the period. Eagle Bay Advisors LLC purchased a new position in shares of Astrazeneca in the fourth quarter valued at about $30,000. YANKCOM Partnership bought a new position in shares of Astrazeneca during the fourth quarter valued at about $31,000. Finally, TFC Financial Management Inc. raised its stake in shares of Astrazeneca by 3,350.0% during the fourth quarter. TFC Financial Management Inc. now owns 345 shares of the company’s stock valued at $32,000 after acquiring an additional 335 shares during the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

AZN has been the topic of several recent analyst reports. Jefferies Financial Group reissued a “buy” rating on shares of Astrazeneca in a research note on Tuesday. Barclays reiterated a “buy” rating on shares of Astrazeneca in a report on Monday, June 1st. Sanford C. Bernstein reiterated a “buy” rating on shares of Astrazeneca in a research report on Monday, May 4th. DZ Bank upgraded Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Wednesday, March 18th. Twelve investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Astrazeneca presently has a consensus rating of “Moderate Buy” and an average price target of $205.33.

Astrazeneca Price Performance

Shares of AZN stock opened at $178.87 on Thursday. The business’s fifty day moving average is $190.12 and its 200 day moving average is $185.76. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. The stock has a market cap of $277.42 billion, a price-to-earnings ratio of 26.86, a PEG ratio of 1.60 and a beta of 0.25. Astrazeneca Plc has a twelve month low of $137.23 and a twelve month high of $212.71.

Astrazeneca (NYSE:AZN) last announced its earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. The firm had revenue of $15.29 billion for the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. Research analysts expect that Astrazeneca Plc will post 9.37 EPS for the current fiscal year.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.